---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-036273"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T17:04:21.998101+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaccitech reports net income of $5.3M for FY2022 vs $50.9M loss in 2021; revenue jumps to $44.7M

## Summary
- Net income attributable to shareholders of $5.3M ($0.14 diluted EPS) vs net loss of $50.9M ($1.94 loss) in 2021.
- Revenue of $44.7M, primarily from AstraZeneca Vaxzevria milestones/royalties, up from $0.3M in 2021.
- Cash of $194.4M at Dec 31, 2022, down from $214.1M; operating cash used $14.4M, capital expenditures $5.8M.
- R&D expenses of $42.4M (up 108% YoY) driven by VTP-300 HBV, SNAPvax programs, and headcount growth.
- Appointed Dr. Nadège Pelletier as CSO in Jan 2023; interim data readouts for VTP-300 and VTP-200 expected in Q1 2023.

## SEC filing metadata
- accession: 0001104659-23-036273
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465923036273/0001104659-23-036273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465923036273/tm2310111d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-036273
- JSON: https://secwatch.observer/filing/0001104659-23-036273.json
- Plain text: https://secwatch.observer/filing/0001104659-23-036273.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported the full year ended December 31, 2022 results: revenue $43.7 million.
  - Period: the full year ended December 31, 2022
  - Revenue: $43.7 million
  - Result: reported results
  source text: The Company’s share of milestone and royalty payments received by Oxford University Innovation (OUI) from AstraZeneca which were recognized as revenue for the year ended December 31, 2022 amounted to $43.7 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000110465923036273/0001104659-23-036273-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.